POZIOTINIB

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C23H21Cl2FN4O3
Molecular Weight	491.342
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC2=NC=NC(NC3=CC=C(Cl)C(Cl)=C3F)=C2C=C1OC4CCN(CC4)C(=O)C=C

InChI

InChIKey=LPFWVDIFUFFKJU-UHFFFAOYSA-N

InChI=1S/C23H21Cl2FN4O3/c1-3-20(31)30-8-6-13(7-9-30)33-19-10-14-17(11-18(19)32-2)27-12-28-23(14)29-16-5-4-15(24)21(25)22(16)26/h3-5,10-13H,1,6-9H2,2H3,(H,27,28,29)

HIDE SMILES / InChI

Molecular Formula	C23H21Cl2FN4O3
Molecular Weight	491.342
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21732342 | https://www.ncbi.nlm.nih.gov/pubmed/27188206

Poziotinib is an inhibitor of EGFR tyrosine kinase family. The drug is being tested in phase II of clinical trials for different cancers: breast cancer, lung adenocarcinoma, head and neck squamous cell carcinoma, HER-2 positive advanced gastric cancer (in combination with Paclitaxel and Trastuzumab).

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Epidermal growth factor receptor 49 Target ID: CHEMBL2363049 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21732342	Inhibitor 8504		3.2 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Breast cancer 432 Sources: https://clinicaltrials.gov/ct2/show/NCT02659514	Primary	Phase II 1147	Unknown Approved Use Unknown
Her2 positive breast cancer 3 Sources: https://clinicaltrials.gov/ct2/show/NCT01746771	Primary	Phase II 1147	Unknown Approved Use Unknown
Head and neck squamous cell carcinoma 32 Sources: https://clinicaltrials.gov/ct2/show/NCT02216916	Primary	Phase II 1147	Unknown Approved Use Unknown
Adenocarcinoma of lung 2 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27188206	Primary	Phase II 1147	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
0.869 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/25377158	32 mg 1 times / day multiple, oral dose: 32 mg route of administration: Oral experiment type: MULTIPLE co-administered:		POZIOTINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
0.989 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/25377158	32 mg 1 times / day multiple, oral dose: 32 mg route of administration: Oral experiment type: MULTIPLE co-administered:		POZIOTINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946	substrate 1193	substrate 1388

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
BCRP 910 P-gp 1741	CYP2E1 729 CYP1A2 1197 CYP2C19 1119

Drug as perpetrator

Target	Modality	Activity
P-gp 1932	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/33158067/ \| https://pubchem.ncbi.nlm.nih.gov/bioassay/1346987#sid=363680279	yes [IC50 11.5821 uM]
BCRP 985	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/33158067/	yes
BCRP 985	supressor 160 Sources: https://pubmed.ncbi.nlm.nih.gov/33158067/	yes

Drug as victim

Target	Modality	Activity
CYP2D6 1388	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/33899675/ \| https://pubmed.ncbi.nlm.nih.gov/23650031/	major
CYP3A4 1946	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/33899675/ \| https://pubmed.ncbi.nlm.nih.gov/23650031/	major
CYP1A2 1197	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/23650031/	minor
CYP2C19 1119	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/23650031/	minor
CYP2C9 1193	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/23650031/	minor
CYP2E1 729	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/23650031/	minor

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY34289	https://www.001chemical.com/chem/1092364-38-9
AA Blocks	AA0039IJ	https://www.aablocks.com/goods/Goods/detail?id=AA0039IJ
Aaron Chemicals	AR003AAB	http://www.aaronchem.com/1092364-38-9
abcr GmbH	AB460678	http://www.abcr.com/shop/en/AB460678
AbMole Bioscience	M5031	http://www.abmole.com/products/poziotinib.html
Accela ChemBio Inc	SY235762	http://www.accelachem.com/cn/search.html?keyword=SY235762&attname=GoodsCode
Aceschem	ACF020020	https://www.aceschem.com/catalog/1092364-38-9.html
Achemtek	0101-001745	http://www.achemtek.com/1092364-38-9
Achemtek	0102-028613	http://www.achemtek.com/1092364-38-9
Acorn PharmaTech	ACN-037459	http://www.acornpharmatech.com/
Adooq BioScience	A13044	https://www.adooq.com/poziotinib.html
Ambinter	Amb22740050	http://www.ambinter.com/reference/22740050
Angel Pharmatech	AG-11220	http://www.angelpharmatech.com/1092364-38-9.html
Angene	AGN-PC-0WAK1C	http://www.angenechemical.com/productshow/AGN-PC-0WAK1C.html
ApexBio Technology	B5827	http://www.apexbt.com/poziotinib.html
Ark Pharm	AK198898	http://www.arkpharminc.com/products/1092364-38-9.html
Ark Pharma Scientific Limited	A-1504	http://www.arkpharmtech.com/product/33455.html
Ark Pharma Scientific Limited	A-1980	http://www.arkpharmtech.com/product/274533.html
Aurora Fine Chemicals LLC	K16.731.286	http://online.aurorafinechemicals.com/info?ID=K16.731.286
Axon MedChem	2920	https://www.axonmedchem.com/product/2920
BioChemPartner	BCP08270	http://www.biochempartner.com/1092364-38-9-BCP08270
BioSynth	J-690026	https://www.biosynth.com/en/products/all-products/products/J-690034.html
BOC Sciences	1092364-38-9	https://www.bocsci.com/poziotinib-cas-1092364-38-9-item-84-462151.html
Boerchem	BC600633	http://www.boerchem.com/?product_43468.html
Chem Scene	CS-3942	http://www.chemscene.com/1092364-38-9.html
ChemShuttle	141917	http://www.chemshuttle.com/catalogsearch/result/?q=1092364-38-9&cat=
Chemspace	CSSB00020668822	https://chem-space.com/CSSB00020668822
Clearsynth	CS-BJ-00012	https://www.clearsynth.com/en/CSBJ00012.html
DC Chemicals	DC7704	http://www.dcchemicals.com/product_show-Poziotinib.html
Debye Scientific	DA-47945	http://www.debyesci.com/cas_1092364-38-9.html
eNovation Chemicals	D408815	https://www.enovationchem.com/ProductDetails.asp?ProductID=D408815
eNovation Chemicals	D580270	https://www.enovationchem.com/ProductDetails.asp?ProductID=D580270
eNovation Chemicals	D696906	https://www.enovationchem.com/ProductDetails.asp?ProductID=D696906
eNovation Chemicals	Y0975710	https://www.enovationchem.com/ProductDetails.asp?ProductID=Y0975710
Excenen	EX-A528	http://www.excenen.com/searchresultlist.php?id=1092364-38-9
Finetech	FT-0752903	http://www.finetechnology-ind.com/prod/detail/pub/1092364-38-9.html
Hairui	HR33170	http://www.hairuichem.com/en/product/1092364-38-9.html
Lab Network	LN01341775	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01341775
MedChem Express	HY-15730	https://www.medchemexpress.com/Poziotinib.html
Molcore	MC34289	https://www.molcore.com/product/1092364-38-9
MolPort	MolPort-035-944-321	https://www.molport.com/shop/molecule-link/MolPort-035-944-321
MuseChem	I000381	https://www.musechem.com/product/I000381.html
Selleck Chemicals	S7358	http://www.selleckchem.com/products/poziotinib-hm781-36b.html
Sinfoo Biotech	S061857	http://www.sinfoobiotech.com/product/1065275
Smolecule	S001711	http://www.smolecule.com/products/s001711
Smolecule	S547961	http://www.smolecule.com/products/s547961
Sun-shine Chemical	Poziotinib	http://www.sun-shinechem.com/Details/Poziotinib/1348/1092364-38-9.html
Synblock Inc	SB16882	http://www.synblock.com/product/1092364-38-9.html
THE BioTek	bt-253485	https://www.thebiotek.com/product/inhibitors/bt-253485
THE BioTek	bt-287238	https://www.thebiotek.com/product/inhibitors/bt-287238
TubePharm	Tube707	http://www.tubepharm.com/product/1092364-38-9-en.html

PubMed

Title	Date	PubMed
Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.	2012-05-15	21732342
Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer.	2011-03-28	21306821

Patents

Sample Use Guides

In Vivo Use Guide

Head and Neck Squamous Cell Carcinoma: Take 45 mg orally, daily and continuously. Lung Adenocarcinoma: patients should receive poziotinib at dose of 16 mg orally once daily in a 28-day cycle.

Route of Administration: Oral

In Vitro Use Guide

HCC827 cells were inhibited on 50% at 1.2 nM of poziotinib; NCI-H358 cells - at 4.8 nM; NCI-H1975 cells - at 5.7 nM; Calu-3 cells - at 2.1 nM; NCI-H1781 cells - at 4 nM; SK-Br3 cells - at 1 nM; NCI-N87 cells - at 0.6 nM.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 07:07:34 GMT 2025` Edited by `admin` on `Wed Apr 02 07:07:34 GMT 2025`
Record UNII	OEI6OOU6IK
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

POZIOTINIB

Official Name

English

HM-781-36

Preferred Name

English

Poziotinib [WHO-DD]

Common Name

English

NOV-1201

Code

English

2-PROPEN-1-ONE, 1-(4-((4-((3,4-DICHLORO-2-FLUOROPHENYL)AMINO)-7-METHOXY-6-QUINAZOLINYL)OXY)-1-PIPERIDINYL)-

Systematic Name

English

1-(4-((4-(3,4-DICHLORO-2-FLUOROANILINO)-7-METHOXYQUINAZOLIN-6-YL)OXY(PIPERIDIN-1-YL)PROP-2-EN-1-ONE

Common Name

English

HM-781-36B

Code

English

NOV-120101

Code

English

poziotinib [INN]

Common Name

English

POZIOTINIB [USAN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1742